Loading
AP
Ange Prostatype Genomics AB Stock: price and insider trades · Sweden
ISIN SE0029529767SE·
Ange Prostatype Genomics AB: what insiders have been doing
This page follows insider dealings at Ange Prostatype Genomics AB as filed with Finansinspektionen. The last twelve months, up to 18 October 2026, brought 9 filings signed by 5 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Over the last twelve months, not one insider purchase of Ange Prostatype Genomics AB stock was filed. Filings reach the Finansinspektionen feed a median of 1 day after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
Across the 886 companies tracked on its exchange, the median is 7 filings; at 9 filings, this issuer sits above that mark.
Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
· cache
Last declaration on 16 September 2026
Declarations9 total
668,000 shares0TeckningsoptionISIN SE0029529767FI:csv-bb9882932bfd83af6576
668,000 shares@ SEK 0.10100.0% of flowInterimsaktieISIN SE0030262895FI:csv-e687c123a581f79e8355
1,437,500 shares0TeckningsoptionISIN SE0029529767FI:csv-df36c3f1769841835ba5
1,437,500 shares@ SEK 0.10100.0% of flowInterimsaktieISIN SE0030262895FI:csv-45ca4b6acf5493993d65
1,437,500 shares0TeckningsoptionISIN SE0029529767FI:csv-dcaf337d8dc6e6916870
1,437,500 shares@ SEK 0.10100.0% of flowInterimsaktieISIN SE0030262895FI:csv-220d4827fcefd6fc6034
5,562,500 shares@ SEK 0.10100.0% of flowInterimsaktieISIN SE0030262895FI:csv-fa1f74b7f0f04ea9c9c4
5,562,500 shares0TeckningsoptionISIN SE0029529767FI:csv-d06ed2b23f004ffc82b4
625,000 shares@ SEK 0.10100.0% of flowTeckningsoptionISIN SE0029529767FI:csv-b097012aa13365ef63fa
9 of 9 declarations
About Ange Prostatype Genomics AB
Ange Prostatype Genomics AB is a company focused on developing genomic tests for prostate cancer. It is listed on the Stockholm Stock Exchange.
